NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older - European Medical Journal

NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older

COVID-19 Vaccine update: learn about the clinical efficacy and safety data for a new recombinant protein subunit COVID-19 vaccine approved and available in >35 countries. The video can be viewed at your convenience.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>